Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Epithelial dysregulation in obese severe asthmatics with gastro-oesophageal reflux.

Perotin JM, Schofield JPR, Wilson SJ, Ward J, Brandsma J, Strazzeri F, Bansal A, Yang X, Rowe A, Corfield J, Lutter R, Shaw DE, Bakke PS, Caruso M, Dahlén B, Fowler SJ, Horváth I, Howarth P, Krug N, Montuschi P, Sanak M, Sandström T, Sun K, Pandis I, Auffray C, De Meulder B, Lefaudeux D, Riley JH, Sousa AR, Dahlen SE, Adcock IM, Chung KF, Sterk PJ, Skipp PJ, Collins JE, Davies DE, Djukanović R; U-BIOPRED Study Group; U-BIOPRED:.

Eur Respir J. 2019 Jun 27;53(6). pii: 1900453. doi: 10.1183/13993003.00453-2019. Print 2019 Jun. No abstract available.

PMID:
31023846
2.

Identification and prospective stability of electronic nose (eNose)-derived inflammatory phenotypes in patients with severe asthma.

Brinkman P, Wagener AH, Hekking PP, Bansal AT, Maitland-van der Zee AH, Wang Y, Weda H, Knobel HH, Vink TJ, Rattray NJ, D'Amico A, Pennazza G, Santonico M, Lefaudeux D, De Meulder B, Auffray C, Bakke PS, Caruso M, Chanez P, Chung KF, Corfield J, Dahlén SE, Djukanovic R, Geiser T, Horvath I, Krug N, Musial J, Sun K, Riley JH, Shaw DE, Sandström T, Sousa AR, Montuschi P, Fowler SJ, Sterk PJ; U-BIOPRED Study Group.

J Allergy Clin Immunol. 2019 May;143(5):1811-1820.e7. doi: 10.1016/j.jaci.2018.10.058. Epub 2018 Dec 6.

PMID:
30529449
3.

Treatable traits in the European U-BIOPRED adult asthma cohorts.

Simpson AJ, Hekking PP, Shaw DE, Fleming LJ, Roberts G, Riley JH, Bates S, Sousa AR, Bansal AT, Pandis I, Sun K, Bakke PS, Caruso M, Dahlén B, Dahlén SE, Horvath I, Krug N, Montuschi P, Sandstrom T, Singer F, Adcock IM, Wagers SS, Djukanovic R, Chung KF, Sterk PJ, Fowler SJ; U-BIOPRED Study Group.

Allergy. 2019 Feb;74(2):406-411. doi: 10.1111/all.13629. Epub 2018 Nov 12. No abstract available.

4.

U-BIOPRED: evaluation of the value of a public-private partnership to industry.

Riley JH, Erpenbeck VJ, Matthews JG, Holweg CTJ, Compton C, Seibold W, Higenbottam T, Wagers S, Rowe A, Myles D; Industry Representatives of the U-BIOPRED Study Group.

Drug Discov Today. 2018 Sep;23(9):1622-1634. doi: 10.1016/j.drudis.2018.06.015. Epub 2018 Jun 21. Review.

PMID:
29936248
5.

Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD.

Singh S, Maltais F, Tombs L, Fahy WA, Vahdati-Bolouri M, Locantore N, Riley JH.

Int J Chron Obstruct Pulmon Dis. 2018 Jan 8;13:203-215. doi: 10.2147/COPD.S145285. eCollection 2018.

6.

Effects of umeclidinium/vilanterol on exercise endurance in COPD: a randomised study.

Riley JH, Kalberg CJ, Donald A, Lipson DA, Shoaib M, Tombs L.

ERJ Open Res. 2018 Jan 5;4(1). pii: 00073-2017. doi: 10.1183/23120541.00073-2017. eCollection 2018 Jan.

7.

Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study.

Feldman GJ, Sousa AR, Lipson DA, Tombs L, Barnes N, Riley JH, Patel S, Naya I, Compton C, Alcázar Navarrete B.

Adv Ther. 2017 Nov;34(11):2518-2533. doi: 10.1007/s12325-017-0626-4. Epub 2017 Nov 1.

8.

Systematic review of the association between exercise tests and patient-reported outcomes in patients with chronic obstructive pulmonary disease.

Punekar YS, Riley JH, Lloyd E, Driessen M, Singh SJ.

Int J Chron Obstruct Pulmon Dis. 2017 Aug 22;12:2487-2506. doi: 10.2147/COPD.S100204. eCollection 2017. Review.

9.

Intracellular interactions of umeclidinium and vilanterol in human airway smooth muscle.

Shaikh N, Johnson M, Hall DA, Chung KF, Riley JH, Worsley S, Bhavsar PK.

Int J Chron Obstruct Pulmon Dis. 2017 Jun 30;12:1903-1913. doi: 10.2147/COPD.S134420. eCollection 2017.

10.

Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study.

Kerwin EM, Kalberg CJ, Galkin DV, Zhu CQ, Church A, Riley JH, Fahy WA.

Int J Chron Obstruct Pulmon Dis. 2017 Feb 24;12:745-755. doi: 10.2147/COPD.S119032. eCollection 2017.

11.

Interpreting patient-reported outcomes from clinical trials in COPD: a discussion.

Jones PW, Rennard S, Tabberer M, Riley JH, Vahdati-Bolouri M, Barnes NC.

Int J Chron Obstruct Pulmon Dis. 2016 Dec 7;11:3069-3078. eCollection 2016. Review.

12.

Correct usage, ease of use, and preference of two dry powder inhalers in patients with COPD: analysis of five phase III, randomized trials.

Riley JH, Tabberer M, Richard N, Donald A, Church A, Harris SS.

Int J Chron Obstruct Pulmon Dis. 2016 Aug 16;11:1873-80. doi: 10.2147/COPD.S109121. eCollection 2016.

13.

The effect of umeclidinium added to inhaled corticosteroid/long-acting β2-agonist in patients with symptomatic COPD: a randomised, double-blind, parallel-group study.

Sousa AR, Riley JH, Church A, Zhu CQ, Punekar YS, Fahy WA.

NPJ Prim Care Respir Med. 2016 Jun 23;26:16031. doi: 10.1038/npjpcrm.2016.31.

14.

Genetic effects on treatment response of umeclidinium/vilanterol in chronic obstructive pulmonary disease.

Condreay L, Huang L, Harris E, Brooks J, Riley JH, Church A, Ghosh S.

Respir Med. 2016 May;114:123-6. doi: 10.1016/j.rmed.2016.03.019. Epub 2016 Apr 1.

15.
16.

Systematic Review of the Association Between Laboratory- and Field-Based Exercise Tests and Lung Function in Patients with Chronic Obstructive Pulmonary Disease.

Bell M, Fotheringham I, Punekar YS, Riley JH, Cockle S, Singh SJ.

Chronic Obstr Pulm Dis. 2015 Jul 8;2(4):321-342. doi: 10.15326/jcopdf.2.4.2014.0157. Review.

17.

Comparison of laboratory- and field-based exercise tests for COPD: a systematic review.

Fotheringham I, Meakin G, Punekar YS, Riley JH, Cockle SM, Singh SJ.

Int J Chron Obstruct Pulmon Dis. 2015 Mar 19;10:625-43. doi: 10.2147/COPD.S70518. eCollection 2015. Review.

18.

Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trials.

Maltais F, Singh S, Donald AC, Crater G, Church A, Goh AH, Riley JH.

Ther Adv Respir Dis. 2014 Dec;8(6):169-81. doi: 10.1177/1753465814559209. Erratum in: Ther Adv Respir Dis. 2016 Jun;10(3):289.

PMID:
25452426
19.

Genetic control of gene expression at novel and established chronic obstructive pulmonary disease loci.

Castaldi PJ, Cho MH, Zhou X, Qiu W, Mcgeachie M, Celli B, Bakke P, Gulsvik A, Lomas DA, Crapo JD, Beaty TH, Rennard S, Harshfield B, Lange C, Singh D, Tal-Singer R, Riley JH, Quackenbush J, Raby BA, Carey VJ, Silverman EK, Hersh CP.

Hum Mol Genet. 2015 Feb 15;24(4):1200-10. doi: 10.1093/hmg/ddu525. Epub 2014 Oct 14.

20.

Altered gene expression in blood and sputum in COPD frequent exacerbators in the ECLIPSE cohort.

Singh D, Fox SM, Tal-Singer R, Bates S, Riley JH, Celli B.

PLoS One. 2014 Sep 29;9(9):e107381. doi: 10.1371/journal.pone.0107381. eCollection 2014.

21.

A diVIsive Shuffling Approach (VIStA) for gene expression analysis to identify subtypes in Chronic Obstructive Pulmonary Disease.

Menche J, Sharma A, Cho MH, Mayer RJ, Rennard SI, Celli B, Miller BE, Locantore N, Tal-Singer R, Ghosh S, Larminie C, Bradley G, Riley JH, Agusti A, Silverman EK, Barabási AL.

BMC Syst Biol. 2014;8 Suppl 2:S8. doi: 10.1186/1752-0509-8-S2-S8. Epub 2014 Mar 13.

22.

Lessons from ECLIPSE: a review of COPD biomarkers.

Faner R, Tal-Singer R, Riley JH, Celli B, Vestbo J, MacNee W, Bakke P, Calverley PM, Coxson H, Crim C, Edwards LD, Locantore N, Lomas DA, Miller BE, Rennard SI, Wouters EF, Yates JC, Silverman EK, Agusti A; ECLIPSE Study Investigators.

Thorax. 2014 Jul;69(7):666-72. doi: 10.1136/thoraxjnl-2013-204778. Epub 2013 Dec 5. Review.

PMID:
24310110
23.

A new class of bronchodilator improves lung function in COPD: a trial with GSK961081.

Wielders PL, Ludwig-Sengpiel A, Locantore N, Baggen S, Chan R, Riley JH.

Eur Respir J. 2013 Oct;42(4):972-81. doi: 10.1183/09031936.00165712. Epub 2013 Feb 21.

24.

Genome-wide association analysis of blood biomarkers in chronic obstructive pulmonary disease.

Kim DK, Cho MH, Hersh CP, Lomas DA, Miller BE, Kong X, Bakke P, Gulsvik A, Agustí A, Wouters E, Celli B, Coxson H, Vestbo J, MacNee W, Yates JC, Rennard S, Litonjua A, Qiu W, Beaty TH, Crapo JD, Riley JH, Tal-Singer R, Silverman EK; ECLIPSE, ICGN, and COPDGene Investigators.

Am J Respir Crit Care Med. 2012 Dec 15;186(12):1238-47. doi: 10.1164/rccm.201206-1013OC. Epub 2012 Nov 9.

25.

Targeted metabolomics identifies perturbations in amino acid metabolism that sub-classify patients with COPD.

Ubhi BK, Cheng KK, Dong J, Janowitz T, Jodrell D, Tal-Singer R, MacNee W, Lomas DA, Riley JH, Griffin JL, Connor SC.

Mol Biosyst. 2012 Oct 30;8(12):3125-33. doi: 10.1039/c2mb25194a.

PMID:
23051772
26.

Metabolic profiling detects biomarkers of protein degradation in COPD patients.

Ubhi BK, Riley JH, Shaw PA, Lomas DA, Tal-Singer R, MacNee W, Griffin JL, Connor SC.

Eur Respir J. 2012 Aug;40(2):345-55. doi: 10.1183/09031936.00112411. Epub 2011 Dec 19.

27.

Genetics of sputum gene expression in chronic obstructive pulmonary disease.

Qiu W, Cho MH, Riley JH, Anderson WH, Singh D, Bakke P, Gulsvik A, Litonjua AA, Lomas DA, Crapo JD, Beaty TH, Celli BR, Rennard S, Tal-Singer R, Fox SM, Silverman EK, Hersh CP; ECLIPSE Investigators.

PLoS One. 2011;6(9):e24395. doi: 10.1371/journal.pone.0024395. Epub 2011 Sep 16.

28.

Induced sputum genes associated with spirometric and radiological disease severity in COPD ex-smokers.

Singh D, Fox SM, Tal-Singer R, Plumb J, Bates S, Broad P, Riley JH, Celli B; ECLIPSE Investigators.

Thorax. 2011 Jun;66(6):489-95. doi: 10.1136/thx.2010.153767. Epub 2011 Mar 24.

PMID:
21441172
29.

Reported pneumonia in patients with COPD: findings from the INSPIRE study.

Calverley PMA, Stockley RA, Seemungal TAR, Hagan G, Willits LR, Riley JH, Wedzicha JA; Investigating New Standards for Prophylaxis in Reduction of Exacerbations (INSPIRE) Investigators.

Chest. 2011 Mar;139(3):505-512. doi: 10.1378/chest.09-2992. Epub 2010 Jun 24.

PMID:
20576732
30.

INPP5E mutations cause primary cilium signaling defects, ciliary instability and ciliopathies in human and mouse.

Jacoby M, Cox JJ, Gayral S, Hampshire DJ, Ayub M, Blockmans M, Pernot E, Kisseleva MV, Compère P, Schiffmann SN, Gergely F, Riley JH, Pérez-Morga D, Woods CG, Schurmans S.

Nat Genet. 2009 Sep;41(9):1027-31. doi: 10.1038/ng.427. Epub 2009 Aug 9.

PMID:
19668215
31.

Probing S4 and S5 segment proximity in mammalian hyperpolarization-activated HCN channels by disulfide bridging and Cd2+ coordination.

Bell DC, Turbendian HK, Valley MT, Zhou L, Riley JH, Siegelbaum SA, Tibbs GR.

Pflugers Arch. 2009 Jun;458(2):259-72. doi: 10.1007/s00424-008-0613-3. Epub 2008 Nov 26.

32.

Deriving probes from large-insert clones by PCR methods.

Albertsen H, Thliveris A, Riley JH, Munroe DJ, Watkins P, Basson CT.

Curr Protoc Hum Genet. 2001 May;Chapter 5:Unit 5.9. doi: 10.1002/0471142905.hg0509s17.

PMID:
18428296
33.

Hamster check pouch--not a mucosal surface!

Riley JH.

Vet Pathol. 2007 Nov;44(6):963-4. No abstract available. Erratum in: Vet Pathol. 2008 Jan;45(1):112.

PMID:
18039916
34.

MORM syndrome (mental retardation, truncal obesity, retinal dystrophy and micropenis), a new autosomal recessive disorder, links to 9q34.

Hampshire DJ, Ayub M, Springell K, Roberts E, Jafri H, Rashid Y, Bond J, Riley JH, Woods CG.

Eur J Hum Genet. 2006 May;14(5):543-8.

35.
36.

A genome-wide search for linkage to asthma phenotypes in the genetics of asthma international network families: evidence for a major susceptibility locus on chromosome 2p.

Pillai SG, Chiano MN, White NJ, Speer M, Barnes KC, Carlsen K, Gerritsen J, Helms P, Lenney W, Silverman M, Sly P, Sundy J, Tsanakas J, von Berg A, Whyte M, Varsani S, Skelding P, Hauser M, Vance J, Pericak-Vance M, Burns DK, Middleton LT, Brewster SR, Anderson WH, Riley JH.

Eur J Hum Genet. 2006 Mar;14(3):307-16. Erratum in: Eur J Hum Genet. 2007 Jun;15(6):714.

37.

A genome-wide scan provides evidence for loci influencing a severe heritable form of common migraine.

Lea RA, Nyholt DR, Curtain RP, Ovcaric M, Sciascia R, Bellis C, Macmillan J, Quinlan S, Gibson RA, McCarthy LC, Riley JH, Smithies YJ, Kinrade S, Griffiths LR.

Neurogenetics. 2005 May;6(2):67-72. Epub 2005 Apr 14.

PMID:
15830246
38.

Pharmacogenetics to predict drug-related adverse events.

Hosford DA, Lai EH, Riley JH, Xu CF, Danoff TM, Roses AD.

Toxicol Pathol. 2004 Mar-Apr;32 Suppl 1:9-12. Review.

PMID:
15209398
39.

Best practices guideline: toxicologic histopathology.

Crissman JW, Goodman DG, Hildebrandt PK, Maronpot RR, Prater DA, Riley JH, Seaman WJ, Thake DC.

Toxicol Pathol. 2004 Jan-Feb;32(1):126-31. No abstract available.

PMID:
14713558
40.

Changes in local S4 environment provide a voltage-sensing mechanism for mammalian hyperpolarization-activated HCN channels.

Bell DC, Yao H, Saenger RC, Riley JH, Siegelbaum SA.

J Gen Physiol. 2004 Jan;123(1):5-19. Epub 2003 Dec 15.

41.

Linkage disequilibrium mapping identifies a 390 kb region associated with CYP2D6 poor drug metabolising activity.

Hosking LK, Boyd PR, Xu CF, Nissum M, Cantone K, Purvis IJ, Khakhar R, Barnes MR, Liberwirth U, Hagen-Mann K, Ehm MG, Riley JH.

Pharmacogenomics J. 2002;2(3):165-75.

42.

Professionalism and professional standards.

Riley JH.

Vet Pathol. 2002 May;39(3):413. No abstract available.

PMID:
12014511
43.

Single-nucleotide polymorphism alleles in the insulin receptor gene are associated with typical migraine.

McCarthy LC, Hosford DA, Riley JH, Bird MI, White NJ, Hewett DR, Peroutka SJ, Griffiths LR, Boyd PR, Lea RA, Bhatti SM, Hosking LK, Hood CM, Jones KW, Handley AR, Rallan R, Lewis KF, Yeo AJ, Williams PM, Priest RC, Khan P, Donnelly C, Lumsden SM, O'Sullivan J, See CG, Smart DH, Shaw-Hawkins S, Patel J, Langrish TC, Feniuk W, Knowles RG, Thomas M, Libri V, Montgomery DS, Manasco PK, Xu CF, Dykes C, Humphrey PP, Roses AD, Purvis IJ.

Genomics. 2001 Dec;78(3):135-49. Erratum in: Genomics 2002 Feb;79(2):271.

PMID:
11735220
44.

The use of single nucleotide polymorphisms in the isolation of common disease genes.

Riley JH, Allan CJ, Lai E, Roses A.

Pharmacogenomics. 2000 Feb;1(1):39-47. Review.

PMID:
11258595
45.

Direct sequencing of bacterial and P1 artificial chromosome-nested deletions for identifying position-specific single-nucleotide polymorphisms.

Chatterjee PK, Yarnall DP, Haneline SA, Godlevski MM, Thornber SJ, Robinson PS, Davies HE, White NJ, Riley JH, Shepherd NS.

Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13276-81.

46.
47.

Construction of a transcription map around the gene for ataxia telangiectasia: identification of at least four novel genes.

Stankovic T, Byrd PJ, Cooper PR, McConville CM, Munroe DJ, Riley JH, Watts GD, Ambrose H, McGuire G, Smith AD, Sutcliffe A, Mills T, Taylor AM.

Genomics. 1997 Mar 1;40(2):267-76.

PMID:
9119394
48.

Method for preparing YAC sublibraries in a plasmid vector.

Trower MK, Purvis IJ, Dykes CW, Riley JH.

Biotechniques. 1996 Mar;20(3):372-4. No abstract available.

49.

Characterization of a YAC contig spanning the pseudoautosomal region.

Ried K, Mertz A, Nagaraja R, Trusgnich M, Riley JH, Anand R, Lehrach H, Page D, Ellison JW, Rappold G.

Genomics. 1995 Oct 10;29(3):787-92.

PMID:
8575778
50.

Administration of recombinant interleukin-12 to mice suppresses hematopoiesis in the bone marrow but enhances hematopoiesis in the spleen.

Tare NS, Bowen S, Warrier RR, Carvajal DM, Benjamin WR, Riley JH, Anderson TD, Gately MK.

J Interferon Cytokine Res. 1995 Apr;15(4):377-83.

PMID:
7627813

Supplemental Content

Loading ...
Support Center